Randomized, double-masked, 2-year comparison of tibolone with 17β-estradiol and norethindrone acetate in preventing postmenopausal bone loss

Osteoporosis International

Volumn 13, Issue 3, 2002, Pages 241-248

  Roux, C ^a   Pelissier, C ^b   Fechtenbaum, J ^a   Loiseau Peres, S ^c   Benhamou, C L ^c  

^a Lab Toxicologie UniversiteRene D   (France)

^b HÔTEL DIEU   (France)

^c INSERM   (France)

Author keywords

Bleeding; Bone mineral density; Breast pain; Hormone replacement; Osteoporosis; Tibolone

Indexed keywords

ESTRADIOL PLUS NORETHISTERONE ACETATE; TIBOLONE;

ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MINERAL; BONE REMODELING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEMUR; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MASTALGIA; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VAGINA BLEEDING; WEIGHT GAIN;

ANDROGEN ANTAGONISTS; BONE DENSITY; BREAST; CALCIUM; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; NORETHINDRONE; NORPREGNENES; OSTEOPOROSIS, POSTMENOPAUSAL; PAIN; PROGESTERONE CONGENERS; STATISTICS, NONPARAMETRIC; UTERINE HEMORRHAGE;

EID: 0036123617     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001980200021     Document Type: Article

References (50)

1. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic
2. Pre-existing fractures and bone mass predict vertebral fracture incidence in women
3. Long-term fracture prediction by bone mineral assessed at different skeletal sites
4. Fracture protection provided by long-term estrogen treatment
5. Hormone replacement therapy and risk of hip fracture, population based case-control study
6. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women: Results of the Danish osteoporosis prevention study
7. Treatment of postmenopausal osteoporosis with transdermal estrogen
8. The effect of postmenopausal estrogen therapy on bone density in elderly women
9. Estrogen replacement therapy and fractures in older women
10. Compliance with hormone replacement therapy (HRT) after screening for postmenopausal osteoporosis
11. Postmenopausal compliance with hormone therapy
12. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy
13. Bone turnover in postmenopausal women after withdrawal of estrogen/gestagen replacement therapy
14. Increased loss of trabecular but not cortical bone density, 1 year after discontinuation of 2 years hormone replacement therapy with tibolone
15. Estrogen and calcium supplement use among Japanese-American women: Effects upon bone loss when used singly and in combination
16. The long-term effectiveness of preventive strategies for osteoporosis in postmenopausal women: A modeling approach
17. Compliance considerations with estrogen replacement: Withdrawal bleeding and other factors
18. Superior compliance and efficacy of continuous combined oral estrogen-progestogen replacement therapy in postmenopausal women
19. Compliance considerations with hormone replacement therapy
20. Combined continuous hormone replacement therapy: A critical review
21. In search of optimal long-term female hormone replacement: The potential of selective estrogen receptor modulators
22. Livial: A review of clinical studies
23. Effect of tibolone on postmenopausal bone loss
24. Tibolone exerts its protective effect on trabecular bone loss through the estrogen receptor
25. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms
26. Org OD 14 and the endometrium
27. A comparative study of two hormone replacement therapy regimens on safety and efficacy variables
28. Impact on uterine bleeding and endomtrial thickness: Tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy
29. The effect of tibolone on proliferation, differentiation and apoptosis in normal breast cells
30. Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: A two-year randomised controlled trial
31. Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures
32. Effects of two doses of tibolone on trabecular and cortical bone loss in early post-menopausal women: A two-year randomized, placebo-controlled study
33. Tibolone: Prevention of bone loss in late postmenopausal women
34. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures
35. Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progestogen therapy in postmenopausal women
36. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17β-estradiol and dydrogesterone
37. A 3-year study of prevention of postmenopausal bone loss: Conjugated equine estrogens plus medroxy progesterone acetate versus tibolone
38. Piperazine oestrone sulphate and interrupted norethistrone in postmenopausal women: Effects on bone mass, lipoprotein metabolism, climacteric symptoms, and adverse effect
39. The effects of low dose norethisterone on biochemical variables in postmenopausal women
40. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
41. Identification of early postmenopausal women with no bone response to HRT: Results of a five-year clinical trial
42. The influence of thinness and smoking on bone loss and response to hormone replacement therapy in early postmenopausal women
43. Tibolone prevents atherosclerotic lesion formation in cholesterol-fed, ovariectomized rabbbits
44. Acute effects of hormone replacement with tibolone on myocardial ischaemia in women with angina
45. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: Analysis of studies published from 1974-2000
46. In spite of dyslipidemia induced by tibolone there is no exacerbation of coronary artery atherosclerosis in atherogenic diet-fed cynomolgus monkeys
47. Tibolone lowers HDL concentrations but does not impair cholesterol efflux from cells
48. Cholesterol efflux potential of serum from atherogenic diet-fed cynomolgus monkeys after long-term tibolone treatment or traditional hormone replacement therapy
49. Resistance of pelvic arteries and plasma lipids in postmenopausal women: Comparative study of tibolone and continuous combined estradiol and norethindrone acetate replacement therapy
50. A combination of low doses of 17β-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women